Article
Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.
The European respiratory journal - 1 Aug 2017
Chen Xinping, Austin Eric D, Talati Megha, Fessel Joshua P, Farber-Eger Eric H, Brittain Evan L, Hemnes Anna R, Loyd James E, West James
Abstract excerpt
Increased oestrogen is a strong epidemiological risk factor for development of pulmonary arterial hypertension (PAH) in patients, associated with metabolic defects. In addition, oestrogens drive penetrance in mice carrying mutations in bone morphogenetic protein receptor type II (BMPR2), the cause of most heritable PAH. The goal of the present study was to determine whether inhibition of oestrogens was effective...
Topics
- Anastrozole
- Animals
- Bone Morphogenetic Protein Receptors, Type II
- Disease Models, Animal
- Echocardiography
- Estradiol
- Estrogen Antagonists
- Female
- Fulvestrant
- Hemodynamics
- Humans
- Hypertension, Pulmonary
- Insulin Resistance